Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells

Oncogene

Volumn 24, Issue 44, 2005, Pages 6719-6728

  Jeong, Soo Jin ^a   Pise Masison, Cynthia A ^a   Radonovich, Michael F ^a   Park, Hyeon Ung ^b   Brady, John N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

AKT; HTLV 1; IKK; NF B; p53; p65

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; TAX PROTEIN;

ARTICLE; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; WILD TYPE;

BCL-X PROTEIN; CELL LINE, TRANSFORMED; CELL SURVIVAL; CELL TRANSFORMATION, VIRAL; CHROMONES; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MORPHOLINES; NF-KAPPA B; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RNA; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 27144477415     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1208825     Document Type: Article

References (44)

1. Akagi T, Ono H and Shimotohno K. (1995). Blood, 86, 4243-4249.
2. Bellacosa A, Testa JR, Staal SP and Tsichlis PN. (1991). Science, 254, 274-277.
3. Cantley LC and Neel BG. (1999). Proc. Natl. Acad. Sci. USA, 96, 4240-4245.
4. Downward J. (2004). Semin. Cell Dev. Biol., 15, 177-182.
5. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR and Greenberg ME. (1997). Science, 275, 661-665.
6. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M. (2004). Cancer Treat. Rev., 30, 193-204.
7. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A and de The G. (1985). Lancet, 2, 407-410.
8. Gills JJ and Dennis PA. (2004). Expert. Opin. Invest. Drugs, 13, 787-797.
9. Grassmann R, Dengler C, Muller-Fleckenstein I, Fleckenstein B, McGuire K, Dokhelar MC, Sodroski JG and Haseltine WA. (1989). Proc. Natl. Acad. Sci. USA, 86, 3351-3355.
10. Hovelmann S, Beckers TL and Schmidt M. (2004). Br. J. Cancer, 90, 2370-2377.
11. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU and Brady JN. (2005). J. Biol. Chem., 280, 10326-10332.
12. Jeong SJ, Radonovich M, Brady JN and Pise-Masison CA. (2004). Blood, 104, 1490-1497.
13. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J and Evan G. (1997). Nature, 385, 544-548.
14. Kulik G, Klippel A and Weber MJ. (1997). Mol. Cell Biol., 17, 1595-1606.
15. Levine AJ. (1997). Cell, 88, 323-331.
16. Liu Y, Wang Y, Yamakuchi M, Masuda S, Tokioka T, Yamaoka S, Maruyama I and Kitajima I. (2001). Oncogene, 20, 2514-2526.
17. Luo J, Manning BD and Cantley LC. (2003). Cancer Cell, 4, 257-262.
18. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin Jr AS and Mayo MW. (2000). Mol. Cell Biol., 20, 1626-1638.
19. Mayo LD and Donner DB. (2002). Trends Biochem. Sci., 27, 462-467.
20. Mochizuki M, Watanabe T, Yamaguchi K, Takatsuki K, Yoshimura K, Shirao M, Nakashima S, Mori S, Araki S and Miyata N. (1992). Jpn. J. Cancer Res., 83, 236-239.
21. Nerenberg M, Hinrichs SH, Reynolds RK, Khoury G and Jay G. (1987). Science, 237, 1324-1329.
22. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y and Osame M. (1989). Lancet, 1, 441.
23. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M and Tara M. (1986). Lancet, 1, 1031-1032.
24. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB. (1999). Nature, 401, 82-85.
25. Parsons R. (2004). Semin. Cell Dev. Biol., 15, 171-176.
26. Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C and Brady JN. (2000). Mol. Cell Biol., 20, 3377-3386.
27. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD and Gallo RC. (1980). Proc. Natl. Acad. Sci. USA, 77, 7415-7419.
28. Raina D, Kharbanda S and Kufe D. (2004). J. Biol. Chem., 279, 20607-20612.
29. Ren S, Gao C, Zhang L, Koike K and Tsuchida N. (2003). Biochem. Biophys. Res. Commun., 308, 120-125.
30. Scheid MP and Woodgett JR. (2003). FEBS Lett., 546, 108-112.
31. Shan X, Czar MJ, Bunnell SC, Liu P, Liu Y, Schwartzberg PL and Wange RL. (2000). Mol. Cell Biol., 20, 6945-6957.
32. Sherr CJ. (1998). Genes Dev., 12, 2984-2991.
33. Sizemore N, Lerner N, Dombrowski N, Sakurai H and Stark GR. (2002). J. Biol. Chem., 277, 3863-3869.
34. Sizemore N, Leung S and Stark GR. (1999). Mol. Cell Biol., 19, 4798-4805.
35. Slee EA, O'Connor DJ and Lu X. (2004). Oncogene, 23, 2809-2818.
36. Songyang Z, Baltimore D, Cantley LC, Kaplan DR and Franke TF. (1997). Proc. Natl. Acad. Sci. USA, 94, 11345-11350.
37. Staal SP, Hartley JW and Rowe WP. (1977). Proc. Natl. Acad. Sci. USA, 74, 3065-3067.
38. Tanaka A, Takahashi C, Yamaoka S, Nosaka T, Maki M and Hatanaka M. (1990). Proc. Natl. Acad. Sci. USA, 87, 1071-1075.
39. Thompson JE and Thompson CB. (2004). J Clin. Oncol., 22, 4217-4226.
40. Vernant JC, Buisson G, Magdeleine J, De Thore J, Jouannelle A, Neisson-Vernant C and Monplaisir N. (1988). Lancet, 1, 177.
41. Vousden KH and Lu X. (2002). Nat. Rev. Cancer, 2, 594-604.
42. Vousden KH. (2000). Cell, 103, 691-694.
43. Yang F, Tang E, Guan K and Wang CY. (2003). J. Immunol., 170, 5630-5635.
44. Yoshida M, Miyoshi I and Hinuma Y. (1982). Proc. Natl. Acad. Sci. USA, 79, 2031-2035.